Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Patients taking GLP-1 therapy often have underlying conditions such as obesity and diabetes that independently increase thrombotic risk
Serine synthesis pathway hyperactivation is mainly restricted to cancer cells due to their high demands for serine and glycine and the downstream products, such as ATP and nucleotides, favoring their uncontrolled proliferation [24, 25]
not available to select directly at checkout 3-month plan: $175/mo 6-month plan: $155/mo Compounded semaglutide (melts) $297 for 30 daily oral dissolving pills 3-month plan: $245/mo for 90 dissolving daily oral pills Compounded tirzepatide (injection) $297 3-month plan: $285/mo 6-month plan: $275/mo Compounded tirzepatide: (microdose) $327 Requires a provider consultation
C., Vance J
Tirzepatide (marketed as Zepbound for weight management and Mounjaro for type 2 diabetes in the UK) is a dual GIP/GLP-1 receptor agonist that has shown similar side effect profiles in clinical trials, including reports of dizziness
It can occur due to the drugs effect on gastrointestinal motility, potentially leading to esophagitis or erosions
